Dengue is mosquito borne viral disease, having no effective antiviral chemotherapy nor approved vaccine available. Therefore the design of new drugs to combat dengue virus replication is a challenge for researchers. Flavanone derivatives and substituted pyrimidine derivatives show antidengue activity in silico and in vitro. We report the docking study, ADME prediction of benzopyranylpyrimidine derivatives against the dengue virus NS2B/NS3 protease. The hydrogen bonding, hydrophobic interactions and Van der Waals forces between designed compounds with Lys74, Trp83, and Leu149 amino acid residues of the NS2B/NS3 protease is also discussed.
